A Phase I, Randomised, 2 Period Cross Over Study to Determine the Comparative Bioavailability of Two Different Oral Formulations of AZD2281 in Cancer Patients With Advanced Solid Tumours

Trial Profile

A Phase I, Randomised, 2 Period Cross Over Study to Determine the Comparative Bioavailability of Two Different Oral Formulations of AZD2281 in Cancer Patients With Advanced Solid Tumours

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Olaparib (Primary)
  • Indications Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Dec 2017 Planned End Date changed from 29 Dec 2017 to 28 Dec 2018.
    • 27 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 17 May 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top